A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma

Trial Profile

A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 13 May 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Mar 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 24 Apr 2008 The expected completion date for this trial is now 1 May 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top